definiens: means all Know - How Controlled byAkcea or its Affiliates on the Execution Date or at any time during the Term necessary or used byAkcea to Exploit the Compound or the Product or disclosed by [COMPANY] to [COMPANY] and, in each casethat specifically relates to ( a ) the composition of matter of the Compound, intermediates or theProduct, or ( b ) methods of using the Compound, intermediates or the Product as a prophylactic, therapeutic or diagnostic ; provided, however, Know - How Controlled by [COMPANY] or any of itsAffiliates that ( i ) consists of subject matter applicable to oligonucleotide compounds or productsin general, or ( ii ) relates to an oligonucleotide compound that does not specifically modulateexpression of ANGPTL3 via the binding, partially or wholly, of such compound to RNA thatencodes ANGPTL3, will not be considered [COMPANY] Product - Specific Know - How . Know - How thatwould otherwise qualify as [COMPANY] Product - Specific Know - How but for clauses ( i ) or ( ii ) will beconsidered [COMPANY] Core Technology Know - How . For clarity, [COMPANY] Product - Specific Know - Howdoes not include any Know - How covering formulation technology or delivery devices ( other thanConjugate Technology )